PHOENIX aims to enable the seamless, timely and cost-friendly transfer of nano-pharmaceuticals from lab bench to clinical trials by providing necessary advanced, affordable and easily accessible services through the Phoenix-OITB (open-innovation test-bed), that will be established as a novel legal entity in 2022.
Phoenix-OITB will offer a Single Entry Point for a consolidated network of facilities, technologies, services and expertise for all the technology transfer aspects from characterization, testing, verification up to scale-up, GMP compliant manufacturing and regulatory guidance.
The developments will we achieved in concrete work on 5 demo-cases with industry and SMEs; two open calls will be issued in the second half of the project.
RECENDT will contribute to the PHOENIX-targets by the development and application of analytical methods in the field of IR- & Raman-spectroscopic technologies, which shall later also be offered in the Phoenix-OITB service portfolio. Further, RECENDT will support in communication, dissemination and reach-out to the existing network in Austria.

Link to Website